Regeneron Pharmaceuticals (REGN) 472.63 $REGN
Stock Market News for April 22, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:10AM CDT
Benchmarks finished Tuesday’s trading session mostly lower following a mixed bag of earnings reports
VRTX: 132.85 (+0.65), UTX: 116.96 (+0.01), KMB: 111.85 (-1.30), MYL: 72.40 (-1.67), AMGN: 169.10 (+0.64), XOM: 87.46 (+0.58), SLB: 92.16 (+0.87), RIG: 16.85 (-0.18), IBM: 165.36 (+1.10), EOG: 97.70 (+1.11), DD: 71.44 (+0.75), TEVA: 63.01 (-1.15), CVX: 109.50 (-0.23), REGN: 472.63 (+9.41), TRV: 102.02 (+0.14)
A Discussion Of Amgen's Q1 Results, With Updates On Its Pipeline
DoctoRx - at Seeking Alpha - Wed Apr 22, 8:28AM CDT
PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41), HSP: 87.80 (+0.04), CELG: 115.54 (+0.72)
Amgen tops estimates with 51 percent spike in 1Q profit
By LINDA A. JOHNSON - AP - Tue Apr 21, 6:27PM CDT
TRENTON, N.J. (AP) — Amgen Inc. boosted its first-quarter profit by 51 percent, thanks to surging drug sales and ongoing cost cuts designed to free up cash for an unprecedented burst of new product launches.
1 Comment
AMGN: 169.10 (+0.64), REGN: 472.63 (+9.41)
Watch for Regeneron Pharmaceuticals to Potentially Pullback After Gaining 2.39% Yesterday
Comtex SmarTrend(R) - Tue Apr 21, 4:14PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $450.02 to a high of $463.73. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $458.30 on volume of 800,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 472.63 (+9.41)
Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 12:30PM CDT
The report "Sinusitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Sinusitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/sinusitis-pi...eport.html .
CBSTZ: 0.06 (unch), REGN: 472.63 (+9.41)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 14.04 (+0.02), FOMX: 10.94 (-0.02), PVCT: 0.90 (unch), JNJ: 100.43 (+0.13), DERM: 15.36 (-0.62), ANAC: 66.45 (-0.22), XNCR: 14.63 (-0.16), REGN: 472.63 (+9.41), AQXP: 7.91 (-0.41), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), VRX.TO: 253.14 (-6.24), CBPO: 99.67 (-0.84), MRK: 57.69 (+0.03), CCXI: 7.86 (-0.02), CLTX: 0.74 (-0.01), CELGZ: 2.87 (+0.04), NVS: 103.45 (-0.62)
Critical Alerts For Advanced Micro Devices, Nuverra Environmental Solutions, Regeneron Pharmaceuticals, Ford and CableVision Systems Released By InvestorsObserver
PR Newswire - Tue Apr 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMD, NES, REGN, F and CVC.
F: 15.91 (+0.09), NES: 3.52 (-0.15), AMD: 2.28 (-0.07), CVC: 18.41 (-0.21), REGN: 472.63 (+9.41)
Jim Cramer's 'Mad Money' Recap: How to Become an Even Better Investor
at The Street - Mon Apr 20, 6:00PM CDT
Cramer's first rule: Diversification is the only way to invest.
DUK: 78.30 (+0.23), SVU: 11.01 (-0.10), FB: 84.63 (+1.01), SKT: 34.36 (+0.07), ED: 61.64 (+0.17), FRT: 140.45 (+0.24), RSH: 0.24 (-0.04), PLKI: 56.99 (-0.03), CELG: 115.54 (+0.72), RAD: 8.32 (+0.39), T: 32.86 (+0.20), S: 5.08 (+0.10), CMG: 641.23 (-51.29), GLD: 113.83 (-1.55), GOOGL: 549.18 (+6.26), VZ: 49.57 (+0.40), AAPL: 128.62 (+1.71), REGN: 472.63 (+9.41)
The 3 Best Stocks for Investing in Cholesterol Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 10:04AM CDT
Statins' cholesterol-lowering ability and a growing global need for cholesterol-busting treatment have turned statins into some of the most widely-prescribed drugs in the world. But until recently, investors hoping to profit from the billions of...
ESPR: 100.53 (-2.60), AMGN: 169.10 (+0.64), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)
Regeneron Pharmaceuticals Falls 2.16% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Apr 17, 4:24PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $442.60 to a high of $455.78. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $445.01 on volume of 675,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 472.63 (+9.41)
Top 50 Big Biotech Partnering and M&A Deal Trends Report 2015
M2 - Thu Apr 16, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxqgzt/top_50_big) has announced the addition of the "Top 50 Big Biotech Partnering and M&A Deal Trends" report to their offering. The Top 50 Big Biotech Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies. Top 50 Big Biotech Partnering and M&A Deal Trends provides the user with the following key benefits: - Detailed partnering activity profiles for each of the top 50 big biotech companies - Over 300 charts showing a company's dealmaking activity since 2009, allowing quick identification potential partners - Partnering therapy focus revealed - Partnering activity since 2010 - number of deals per year - Full listing of partnering deals - Activity by deal type - Activity by industry sector - Activity by phase of development - Activity by technology type - Activity by therapeutic area - Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available - Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents - Understand the key deal terms the company has agreed in previous deals - Undertake due diligence to assess suitability of your proposed deal terms for partner companies Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Big biotech top 50 dealmaking activity Chapter 3 - Top big biotech deals by value Chapter 4 - Submitting Opportunities to Big biotech Chapter 5 - Forthcoming big biotech partnering events Chapter 6 - Big Biotech Company Profiles - 30 of the 50 companies - Acorda Therapeutics - Actavis - Actelion - Alexion Pharmaceuticals - Alkermes - Allergan - Amgen - Bavarian Nordic - Biocon - Biogen Idec - BioMarin Pharmaceuticals - Celgene - CSL - Cubist - Genmab - Gilead Sciences - Isis Pharmaceuticals - Jaxx Pharmaceuticals - LFB Group - Medivation - PDL BioPharma - Pharmacyclics - Questcor Pharmaceuticals - Regeneron Pharmaceuticals - Roche - Salix Pharmaceuticals - SciClone Pharmaceuticals - Seattle Genetics - Shire - Vertex Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/dxqgzt/top_50_big
BIIB: 423.57 (+1.46), VRTX: 132.85 (+0.65), SLXP: 172.96 (+0.15), AMGN: 169.10 (+0.64), ACOR: 33.34 (-1.33), ALKS: 62.60 (-0.24), PDLI: 7.07 (unch), AGN: 240.22 (+2.88), ISIS: 66.26 (-0.03), GILD: 104.18 (-1.02), ALXN: 188.19 (+1.41), SCLN: 8.99 (+0.04), REGN: 472.63 (+9.41), CELGZ: 2.87 (+0.04)
Monoclonal Antibodies Partnering Deals, Terms and Agreements 2010-2015
M2 - Thu Apr 16, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m7zvsb/monoclonal) has announced the addition of the "Monoclonal Antibodies Partnering Terms and Agreements" report to their offering. The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest monoclonal antibody deals announced in the healthcare sectors. This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in monoclonal antibody dealmaking Chapter 3 - Leading monoclonal antibody deals Chapter 4 - Big pharma monoclonal antibody deals Chapter 5 - Big biotech monoclonal antibodies deals Chapter 6 - Monoclonal antibody contracts dealmaking directory Chapter 7 - Monoclonal antibody deals by individual technology type Chapter 8 - Monoclonal antibody partnering resource center Companies Mentioned - Partial List - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Servier - Shionogi - Takeda - Teva - Alexion Pharmaceuticals - Elan - Emergent BioSolutions - Galapagos - Genmab - LFB Group - Morphosys - Novo Nordisk - PDL BioPharma - Regeneron Pharmaceuticals - Seattle Genetics - Spectrum Pharmaceuticals - Swedish Orphan Biovitrum - ADMA Biologics - Alexion Pharmaceuticals - Amgen - AstraZeneca - Avecia Biologics - AVEO Pharmaceuticals - Biotest - Boehringer Ingelheim For more information visit http://www.researchandmarkets.com/research/m7zvsb/monoclonal
NVO: 56.37 (-0.17), EBS: 29.84 (-0.13), ADMA: 8.98 (-0.03), AVEO: 2.04 (+0.12), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), SPPI: 5.98 (+0.04), REGN: 472.63 (+9.41), PDLI: 7.07 (unch)
3 Potential Blockbuster Drugs That Could Be Approved Before Year's End
Brian Orelli, Dan Caplinger, and Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 16, 7:58AM CDT
The only thing more exciting than a binary event for a drugmaker is one that could result in $1 billion or more in sales, the threshold for being called a blockbuster. We asked our team of healthcare experts to name a drug that's up for approval that...
VRTX: 132.85 (+0.65), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41), NVS: 103.45 (-0.62)
Big Pharmas' Dirty Little Secret About Cholesterol Lowering Drugs
Mark Chapman - at Seeking Alpha - Wed Apr 15, 10:19AM CDT
ESPR: 100.53 (-2.60), ALNY: 118.00 (-2.70), MDCO: 27.84 (+0.25), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)
Earnings And GDP Temporarily Take Investor Spotlight Off The Fed
Scott Martindale - Seeking Alpha - Mon Apr 13, 9:36AM CDT
As we get into the heart of earnings season and anticipate the GDP report for Q1, the investor spotlight has been taken off the Federal Reserve and timing of its first interest rate hike, at least temporarily. Even though Q1 economic growth will...
AMBA: 74.57 (+0.18), IYK: 107.48 (+0.19), IYJ: 109.12 (+0.41), VRX: 206.93 (-3.92), IYH: 157.86 (+0.08), SWKS: 96.83 (+1.41), PACW: 45.57 (-0.11), FBT: 121.09 (-0.27), IYM: 83.73 (+0.19), QABA: 36.98 (+0.02), IYC: 144.75 (+0.26), IYF: 89.68 (+0.76), IYE: 46.11 (+0.28), FMER: 19.43 (+0.20), IYZ: 31.45 (+0.10), SPY: 210.63 (+1.03), IDU: 111.81 (+0.27), TDIV: 27.94 (+0.20), REGN: 472.63 (+9.41), IYW: 107.77 (+0.94)
10 Largest Companies by Market Cap in Biotech
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 11, 2:02PM CDT
Source: Celgene Big bucks are being made in biotech. That's clear from the sizzling performance of the industry. If five years ago you had invested $1,000 each in the current 10 biggest biotechs in terms of market cap, you would now have over...
BIIB: 423.57 (+1.46), VRTX: 132.85 (+0.65), PCYC: 256.98 (-0.77), BMRN: 121.08 (-0.16), GILD: 104.18 (-1.02), INCY: 107.98 (-1.20), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91), REGN: 472.63 (+9.41), CELG: 115.54 (+0.72)
Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2015
PR Newswire - Fri Apr 10, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2015 financial and operating results on Thursday, May 7, 2015, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
REGN: 472.63 (+9.41)
Stock Market News for April 22, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:10AM CDT
Benchmarks finished Tuesday’s trading session mostly lower following a mixed bag of earnings reports
VRTX: 132.85 (+0.65), UTX: 116.96 (+0.01), KMB: 111.85 (-1.30), MYL: 72.40 (-1.67), AMGN: 169.10 (+0.64), XOM: 87.46 (+0.58), SLB: 92.16 (+0.87), RIG: 16.85 (-0.18), IBM: 165.36 (+1.10), EOG: 97.70 (+1.11), DD: 71.44 (+0.75), TEVA: 63.01 (-1.15), CVX: 109.50 (-0.23), REGN: 472.63 (+9.41), TRV: 102.02 (+0.14)
A Discussion Of Amgen's Q1 Results, With Updates On Its Pipeline
DoctoRx - at Seeking Alpha - Wed Apr 22, 8:28AM CDT
PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41), HSP: 87.80 (+0.04), CELG: 115.54 (+0.72)
Amgen tops estimates with 51 percent spike in 1Q profit
By LINDA A. JOHNSON - AP - Tue Apr 21, 6:27PM CDT
TRENTON, N.J. (AP) — Amgen Inc. boosted its first-quarter profit by 51 percent, thanks to surging drug sales and ongoing cost cuts designed to free up cash for an unprecedented burst of new product launches.
1 Comment
AMGN: 169.10 (+0.64), REGN: 472.63 (+9.41)
Watch for Regeneron Pharmaceuticals to Potentially Pullback After Gaining 2.39% Yesterday
Comtex SmarTrend(R) - Tue Apr 21, 4:14PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $450.02 to a high of $463.73. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $458.30 on volume of 800,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 472.63 (+9.41)
Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 12:30PM CDT
The report "Sinusitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Sinusitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/sinusitis-pi...eport.html .
CBSTZ: 0.06 (unch), REGN: 472.63 (+9.41)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 14.04 (+0.02), FOMX: 10.94 (-0.02), PVCT: 0.90 (unch), JNJ: 100.43 (+0.13), DERM: 15.36 (-0.62), ANAC: 66.45 (-0.22), XNCR: 14.63 (-0.16), REGN: 472.63 (+9.41), AQXP: 7.91 (-0.41), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), VRX.TO: 253.14 (-6.24), CBPO: 99.67 (-0.84), MRK: 57.69 (+0.03), CCXI: 7.86 (-0.02), CLTX: 0.74 (-0.01), CELGZ: 2.87 (+0.04), NVS: 103.45 (-0.62)
Critical Alerts For Advanced Micro Devices, Nuverra Environmental Solutions, Regeneron Pharmaceuticals, Ford and CableVision Systems Released By InvestorsObserver
PR Newswire - Tue Apr 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMD, NES, REGN, F and CVC.
F: 15.91 (+0.09), NES: 3.52 (-0.15), AMD: 2.28 (-0.07), CVC: 18.41 (-0.21), REGN: 472.63 (+9.41)
Jim Cramer's 'Mad Money' Recap: How to Become an Even Better Investor
at The Street - Mon Apr 20, 6:00PM CDT
Cramer's first rule: Diversification is the only way to invest.
DUK: 78.30 (+0.23), SVU: 11.01 (-0.10), FB: 84.63 (+1.01), SKT: 34.36 (+0.07), ED: 61.64 (+0.17), FRT: 140.45 (+0.24), RSH: 0.24 (-0.04), PLKI: 56.99 (-0.03), CELG: 115.54 (+0.72), RAD: 8.32 (+0.39), T: 32.86 (+0.20), S: 5.08 (+0.10), CMG: 641.23 (-51.29), GLD: 113.83 (-1.55), GOOGL: 549.18 (+6.26), VZ: 49.57 (+0.40), AAPL: 128.62 (+1.71), REGN: 472.63 (+9.41)
The 3 Best Stocks for Investing in Cholesterol Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 10:04AM CDT
Statins' cholesterol-lowering ability and a growing global need for cholesterol-busting treatment have turned statins into some of the most widely-prescribed drugs in the world. But until recently, investors hoping to profit from the billions of...
ESPR: 100.53 (-2.60), AMGN: 169.10 (+0.64), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)
Regeneron Pharmaceuticals Falls 2.16% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Apr 17, 4:24PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $442.60 to a high of $455.78. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $445.01 on volume of 675,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 472.63 (+9.41)
Top 50 Big Biotech Partnering and M&A Deal Trends Report 2015
M2 - Thu Apr 16, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxqgzt/top_50_big) has announced the addition of the "Top 50 Big Biotech Partnering and M&A Deal Trends" report to their offering. The Top 50 Big Biotech Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies. Top 50 Big Biotech Partnering and M&A Deal Trends provides the user with the following key benefits: - Detailed partnering activity profiles for each of the top 50 big biotech companies - Over 300 charts showing a company's dealmaking activity since 2009, allowing quick identification potential partners - Partnering therapy focus revealed - Partnering activity since 2010 - number of deals per year - Full listing of partnering deals - Activity by deal type - Activity by industry sector - Activity by phase of development - Activity by technology type - Activity by therapeutic area - Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available - Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents - Understand the key deal terms the company has agreed in previous deals - Undertake due diligence to assess suitability of your proposed deal terms for partner companies Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Big biotech top 50 dealmaking activity Chapter 3 - Top big biotech deals by value Chapter 4 - Submitting Opportunities to Big biotech Chapter 5 - Forthcoming big biotech partnering events Chapter 6 - Big Biotech Company Profiles - 30 of the 50 companies - Acorda Therapeutics - Actavis - Actelion - Alexion Pharmaceuticals - Alkermes - Allergan - Amgen - Bavarian Nordic - Biocon - Biogen Idec - BioMarin Pharmaceuticals - Celgene - CSL - Cubist - Genmab - Gilead Sciences - Isis Pharmaceuticals - Jaxx Pharmaceuticals - LFB Group - Medivation - PDL BioPharma - Pharmacyclics - Questcor Pharmaceuticals - Regeneron Pharmaceuticals - Roche - Salix Pharmaceuticals - SciClone Pharmaceuticals - Seattle Genetics - Shire - Vertex Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/dxqgzt/top_50_big
BIIB: 423.57 (+1.46), VRTX: 132.85 (+0.65), SLXP: 172.96 (+0.15), AMGN: 169.10 (+0.64), ACOR: 33.34 (-1.33), ALKS: 62.60 (-0.24), PDLI: 7.07 (unch), AGN: 240.22 (+2.88), ISIS: 66.26 (-0.03), GILD: 104.18 (-1.02), ALXN: 188.19 (+1.41), SCLN: 8.99 (+0.04), REGN: 472.63 (+9.41), CELGZ: 2.87 (+0.04)
Monoclonal Antibodies Partnering Deals, Terms and Agreements 2010-2015
M2 - Thu Apr 16, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m7zvsb/monoclonal) has announced the addition of the "Monoclonal Antibodies Partnering Terms and Agreements" report to their offering. The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest monoclonal antibody deals announced in the healthcare sectors. This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in monoclonal antibody dealmaking Chapter 3 - Leading monoclonal antibody deals Chapter 4 - Big pharma monoclonal antibody deals Chapter 5 - Big biotech monoclonal antibodies deals Chapter 6 - Monoclonal antibody contracts dealmaking directory Chapter 7 - Monoclonal antibody deals by individual technology type Chapter 8 - Monoclonal antibody partnering resource center Companies Mentioned - Partial List - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Servier - Shionogi - Takeda - Teva - Alexion Pharmaceuticals - Elan - Emergent BioSolutions - Galapagos - Genmab - LFB Group - Morphosys - Novo Nordisk - PDL BioPharma - Regeneron Pharmaceuticals - Seattle Genetics - Spectrum Pharmaceuticals - Swedish Orphan Biovitrum - ADMA Biologics - Alexion Pharmaceuticals - Amgen - AstraZeneca - Avecia Biologics - AVEO Pharmaceuticals - Biotest - Boehringer Ingelheim For more information visit http://www.researchandmarkets.com/research/m7zvsb/monoclonal
NVO: 56.37 (-0.17), EBS: 29.84 (-0.13), ADMA: 8.98 (-0.03), AVEO: 2.04 (+0.12), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), SPPI: 5.98 (+0.04), REGN: 472.63 (+9.41), PDLI: 7.07 (unch)
3 Potential Blockbuster Drugs That Could Be Approved Before Year's End
Brian Orelli, Dan Caplinger, and Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 16, 7:58AM CDT
The only thing more exciting than a binary event for a drugmaker is one that could result in $1 billion or more in sales, the threshold for being called a blockbuster. We asked our team of healthcare experts to name a drug that's up for approval that...
VRTX: 132.85 (+0.65), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41), NVS: 103.45 (-0.62)
Big Pharmas' Dirty Little Secret About Cholesterol Lowering Drugs
Mark Chapman - at Seeking Alpha - Wed Apr 15, 10:19AM CDT
ESPR: 100.53 (-2.60), ALNY: 118.00 (-2.70), MDCO: 27.84 (+0.25), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)
Earnings And GDP Temporarily Take Investor Spotlight Off The Fed
Scott Martindale - Seeking Alpha - Mon Apr 13, 9:36AM CDT
As we get into the heart of earnings season and anticipate the GDP report for Q1, the investor spotlight has been taken off the Federal Reserve and timing of its first interest rate hike, at least temporarily. Even though Q1 economic growth will...
AMBA: 74.57 (+0.18), IYK: 107.48 (+0.19), IYJ: 109.12 (+0.41), VRX: 206.93 (-3.92), IYH: 157.86 (+0.08), SWKS: 96.83 (+1.41), PACW: 45.57 (-0.11), FBT: 121.09 (-0.27), IYM: 83.73 (+0.19), QABA: 36.98 (+0.02), IYC: 144.75 (+0.26), IYF: 89.68 (+0.76), IYE: 46.11 (+0.28), FMER: 19.43 (+0.20), IYZ: 31.45 (+0.10), SPY: 210.63 (+1.03), IDU: 111.81 (+0.27), TDIV: 27.94 (+0.20), REGN: 472.63 (+9.41), IYW: 107.77 (+0.94)
10 Largest Companies by Market Cap in Biotech
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 11, 2:02PM CDT
Source: Celgene Big bucks are being made in biotech. That's clear from the sizzling performance of the industry. If five years ago you had invested $1,000 each in the current 10 biggest biotechs in terms of market cap, you would now have over...
BIIB: 423.57 (+1.46), VRTX: 132.85 (+0.65), PCYC: 256.98 (-0.77), BMRN: 121.08 (-0.16), GILD: 104.18 (-1.02), INCY: 107.98 (-1.20), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91), REGN: 472.63 (+9.41), CELG: 115.54 (+0.72)
Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2015
PR Newswire - Fri Apr 10, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2015 financial and operating results on Thursday, May 7, 2015, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
REGN: 472.63 (+9.41)
